To test whether macropinocytosis was involved in the SARS-CoV-2 life cycle, we used a panel of compounds to treat the cells prior to viral infection, which includes 5-(N-ethyl-N-isopropyl) amiloride (EIPA), an inhibitor of macropinocytosis that targets NHE to block the macropinocytosis pathway, chlorpromazine hydrochloride (CPZ), a commonly used compound to inhibit clathrin-mediated endocytosis, and methyl-β-cyclodextrin (MβCD), an inhibitor of cholesterol-rich lipid rafts that depletes cholesterol. Here, SLC9C1 is linked to viral infectious disease.